RE:RE:RE:RE:RE:Communication with share holdersThis is how CYDY handle the market, note they will be answering questions from analysts and investors, transparent and informative.
"
Management will provide an update on recent clinical and regulatory developments regarding COVID-19 clinical trials, along with other strategic priorities: 1) BLA/MAA submissions to Health Canada, MHRA, EMA, and US FDA
2) HIV prevention trial/monotherapy trial
3) Potential revenue from HIV and manufacturing forecast
4) HIV Cure - amfAR
5) EUA submission timelines to same four agencies for COVID-19, if CD12 Trial results are supportive of an EUA
6) Long-hauler clinical trial and potential data readout timelines
7) NASH trial and potential interim analysis timeline
8) Cancer trial Breakthrough Therapy designation potential timelines
9) GvHD trial status
10) Stroke/MS new trials in 2021
11) NASDAQ uplisting status
Management will also provide approximately 30-45 minutes to address questions submitted online by analysts and investors."